Myrtle Potter is the Chief Executive Ofﬁcer at Sumitovant Biopharma, Inc., a global, multibillion-dollar biopharmaceutical company.
In this role, Potter oversees strategy, investment and operations for ﬁve biopharmaceutical companies: Myovant, Urovant, Enzyvant, Altavant and Spirovant in the Sumitovant Biopharma family of companies. These companies span multiple therapeutic areas and modalities, including monoclonal antibodies, gene therapies, regenerative therapies and small molecules.
Prior to Sumitovant Biopharma, Potter served as CEO of Myrtle Potter & Company, a healthcare advisory ﬁ rm that she started in 2005.
Potter previously served as President and COO of Genentech and President of U.S. Cardiovascular/ Metabolics at Bristol-Myers Squibb.
Potter serves on the boards of several Sumitovant Biopharma family biopharmaceutical companies, including Myovant Sciences, Urovant Sciences, Axovant Gene Therapies and Arbutus Biopharma.
Potter is a trustee and earned her Bachelor of Arts from The University of Chicago.